The target of investment activities is to achieve long-term value increase on the invested assets through active asset management pursuant to the Act on Common Funds and the fund's regulations.
The assets are invested in publicly traded equities and equity-linked securities of pharmaceutical, healthcare and biotechnology companies globally. The assets may also be invested in securities whose issuer's primary business is related to ageing or quality of life, or serves or supports these sectors. The fund is categorized under SFDR as article 8 and promotes environmental and social characteristics, as well as good governance practices, through screening, restrictions, investment analysis and decision-making as well as active ownership. The fund follows Danske Invest’s responsible investment policy. The returns on the fund's investments, such as dividends and interest, will be reinvested. The fund's base currency is the euro.
It is generally expected that the fund's holdings, and therefore its performance, may differ significantly from those of the benchmark. The fund is suitable for investors who wish to invest globally in pharmaceutical and other healthcare sector companies and who seek high returns, while tolerating substantial value fluctuations or even decreases. The fund is suitable as part of a diversified investment portfolio. Investors may subscribe for and redeem fund units on every banking day.
Recommendation: This fund may not be appropriate for investors who plan to withdraw their money within 7 years.